I think my research is better than the research I have seen on these threads.
the waffle that at first Ebioscience is going to make the company cash flow positive, then the BBI story that pumped the sp to 28 c and now everyone is hanging on to POC1 with 10 million revenue.
Very easy to namecall my research but Philips market share for POCT is going to be very small at best.
They have absolutely zero market share atm and only a troponin test on trial thats even on the face of their claims offer dubious advantage in patient care over the existing options.
SP should be 5c WITH a POC1 deal, page-15
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.3¢ |
Change
0.001(4.55%) |
Mkt cap ! $56.67M | |||
| Open | High | Low | Value | Volume |
| 2.3¢ | 2.3¢ | 2.2¢ | $7.175K | 316.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 2237568 | 2.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.3¢ | 592176 | 5 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
2.3¢ |
Change
0.001 ( 4.55 %) |
||||
| Open | High | Low | Volume | ||
| 2.2¢ | 2.3¢ | 2.2¢ | 1213592 | ||
| Last updated 15.59pm 17/05/2024 ? | |||||
| ADO (ASX) Chart |